Company Cash Funds: Hepion Pharmaceuticals (HEPA)

Public company logo of Hepion Pharmaceuticals (HEPA)

Hepion Pharmaceuticals relies on investment capital to fund its clinical trials. The key asset is rencofilstat, a drug targeting liver inflammation and fibrosis. A highly specialized staff of experts is supported by external consulting. The GURU.Markets system displays a cash accumulation chart, where 0.00 represents the current value of the company's liquidity metric.

hepionpharma.com - HEPA Company Cash Balance (period 07/04/2022 - 06/14/2025)

Financial and market metric breakdowns for Hepion Pharmaceuticals (HEPA)

- stock value and consensus price forecast:
- company stock exchange capitalization indicators:
Comprehensive company analysis:HEPA Hepion Pharmaceuticals
Brand item of Hepion Pharma

This indicator measures immediate liquidity, determining the business's ability to cover obligations without resorting to external financing. The metric aggregates account balances and highly liquid equivalents, reflecting the actual margin of safety. By analyzing cash reserve dynamics, an investor can identify the critical burn rate. For Hepion Pharmaceuticals (HEPA), this trend becomes decisive amid the cessation of primary developments. The current cash balance now merely reflects the pace of asset liquidation while the company seeks strategic alternatives.